CONTACT US
Home > APIs>Endocrinology and Hormones>Keap1-Nrf2> > Ezetimibe
163222-33-1-Ezetimibe Ezetimibe

Ezetimibe

For research use only. Not for therapeutic Use.

  • CAT Number: A000268
  • CAS Number: 163222-33-1
  • Molecular Formula: C₂₄H₂₁F₂NO₃
  • Molecular Weight: 409.43
  • Purity: ≥95%
Inquiry Now
Related Small Molecules: (4-Methylpiperidin-4-yl)methanol     3-Methyl-5-(piperidin-4-yl)pyridine     Ropivacaine Hydrochloride    
Research Areas: Lipid Metabolism     Metabolic Disease Research    

Ezetimibe is a drug that lowers plasma cholesterol levels. It acts by decreasing cholesterol absorption in the small intestine. It may be used alone when other cholesterol-lowering medications are not tolerated, or together with statins (e.g., ezetimibe/simvastatin) when statins alone do not control cholesterol. Ezetimibe is recommended as second line therapy for those intolerant of statins or unable to achieve target LDL cholesterol levels on statins alone by several major medical group practice guidelines, but not by those of the American Heart Association and American College of Cardiology.


Catalog Number A000268
CAS Number 163222-33-1
Synonyms

163222-33-1; Zetia; Ezetrol; Ezedoc; Ezetimib

Molecular Formula C₂₄H₂₁F₂NO₃
Purity ≥95%
Target Autophagy
Solubility >20.5mg/mL in DMSO
Storage -20°C
InChI InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1
InChIKey OLNTVTPDXPETLC-XPWALMASSA-N
SMILES C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O
Reference

1: Kobberø Lauridsen B, Stender S, Frikke-Schmidt R, Nordestgaard BG,
Tybjærg-Hansen A. Using genetics to explore whether the cholesterol-lowering drug
ezetimibe may cause an increased risk of cancer. Int J Epidemiol. 2017 Jun 30.
doi: 10.1093/ije/dyx096. [Epub ahead of print] PubMed PMID: 29106532.
<br>

2: Stefanutti C, Mazza F, Mesce D, Morozzi C, Di Giacomo S, Vitale M, Pergolini
M. Monascus purpureus for statin and ezetimibe intolerant heterozygous familial
hypercholesterolaemia patients: A clinical study. Atheroscler Suppl. 2017
Nov;30:86-91. doi: 10.1016/j.atherosclerosissup.2017.05.021. PubMed PMID:
29096866.
<br>

3: Ruel I, Aljenedil S, Sadri I, de Varennes é, Hegele RA, Couture P, Bergeron J,
Wanneh E, Baass A, Dufour R, Gaudet D, Brisson D, Brunham LR, Francis GA,
Cermakova L, Brophy JM, Ryomoto A, Mancini GBJ, Genest J. Imputation of Baseline
LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on
Statins or Ezetimibe. Clin Chem. 2017 Oct 16. pii: clinchem.2017.279422. doi:
10.1373/clinchem.2017.279422. [Epub ahead of print] PubMed PMID: 29038147.

<br>
4: Bergland Ellingsen S, Nordmo E, Tore Lappeg&#229;rd K. Recurrence and Severe
Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination
With Ezetimibe. Clin Med Insights Case Rep. 2017 Sep 25;10:1179547617731375. doi:
10.1177/1179547617731375. eCollection 2017. PubMed PMID: 28979175; PubMed Central
PMCID: PMC5617085.
<br>

5: Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA,
Mach F, Van de Werf FJ, Dalby AJ, White HD, Tershakovec AM, Cannon CP, Braunwald
E. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in
Patients with Acute Coronary Syndrome in IMPROVE-IT. Circulation. 2017 Sep 30.
pii: CIRCULATIONAHA.117.029095. doi: 10.1161/CIRCULATIONAHA.117.029095. [Epub
ahead of print] PubMed PMID: 28972004.
<br>

6: Guimar&#227;es ES, Cerda A, Dorea EL, Bernik MMS, Gusukuma MC, Pinto GA, Fajardo
CM, Hirata MH, Hirata RDC. Effects of short-term add-on ezetimibe to statin
treatment on expression of adipokines and inflammatory markers in diabetic and
dyslipidemic patients. Cardiovasc Ther. 2017 Sep 21. doi:
10.1111/1755-5922.12307. [Epub ahead of print] PubMed PMID: 28940978.

<br>
7: Kim SH, Kim G, Han DH, Lee M, Kim I, Kim B, Kim KH, Song YM, Yoo JE, Wang HJ,
Bae SH, Lee YH, Lee BW, Kang ES, Cha BS, Lee MS. Ezetimibe ameliorates
steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of
autophagy and NLRP3 inflammasome inhibition. Autophagy. 2017 Oct
3;13(10):1767-1781. doi: 10.1080/15548627.2017.1356977. Epub 2017 Sep 21. PubMed
PMID: 28933629; PubMed Central PMCID: PMC5640190.

<br>
8: Bove M, Fogacci F, Cicero AFG. Pharmacokinetic drug evaluation of ezetimibe +
simvastatin for the treatment of hypercholesterolemia. Expert Opin Drug Metab
Toxicol. 2017 Oct;13(10):1099-1104. doi: 10.1080/17425255.2017.1381085. Epub 2017
Sep 26. Review. PubMed PMID: 28922021.
<br>

9: Lin XL, Liu MH. Statin and ezetimibe combination therapy: New therapeutic
options for lowering Low-Density Lipoprotein Cholesterol. Int J Cardiol. 2017 Nov
15;247:49. doi: 10.1016/j.ijcard.2017.06.118. PubMed PMID: 28916087.

<br>
10: Freitas Gouveia M, Trüeb RM. Unsuccessful Treatment of Alopecia Areata with
Simvastatin/Ezetimibe: Experience in 12 Patients. Skin Appendage Disord. 2017
Aug;3(3):156-160. doi: 10.1159/000468991. Epub 2017 Apr 22. PubMed PMID:
28879192; PubMed Central PMCID: PMC5582473.

Request a Quote